GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹800 Cr | ₹1,063 Cr | ₹337 Cr | ₹361 Cr | ₹384 Cr |
What is the latest Contingent Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹800 Cr |
| Mar2024 | ₹1,063 Cr |
| Mar2023 | ₹337 Cr |
| Mar2022 | ₹361 Cr |
| Mar2021 | ₹384 Cr |
How is Contingent Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹800 Cr | -24.74 | |
| Mar2024 | ₹1,063 Cr | 215.81 | |
| Mar2023 | ₹337 Cr | -6.81 | |
| Mar2022 | ₹361 Cr | -5.96 | |
| Mar2021 | ₹384 Cr | - | |
Compare Contingent Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹57,529.3 Cr | 3.7% | 10.5% | 30.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹424,982.0 Cr | -0.7% | -0.5% | -3.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,878.0 Cr | 2.8% | 2.2% | 10.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹129,095.0 Cr | 1.5% | 3.4% | 12.4% | Stock Analytics | |
| CIPLA | ₹122,175.0 Cr | 0.8% | 0.1% | 3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,154.0 Cr | 0.4% | 3.2% | 0.3% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 3.7% |
10.5% |
30.6% |
| SENSEX | 0.4% |
-0.1% |
6.1% |
You may also like the below Video Courses